NCT06992505 (AMETISTA) is a clinical trial in Macrophage Activation Syndrome (MAS), sponsored by Swedish Orphan Biovitrum.

Who is sponsoring NCT06992505?

NCT06992505 is sponsored by Swedish Orphan Biovitrum.

What condition does NCT06992505 study?

NCT06992505 studies Macrophage Activation Syndrome (MAS), Still Disease, Juvenile Onset, Still's Disease, Adult-Onset.

Is NCT06992505 still recruiting?

NCT06992505 is currently completed. Last updated 2 December 2025.

Last reviewed 2025-12-02 · How we verify

NCT06992505: AMETISTA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessment of Macrophage Activation syndromE in STill's Disease in Italy

Completed Last updated 2 December 2025

What this trial tests

trial in Macrophage Activation Syndrome (MAS) in 32 participants. Completed in 27 November 2025.

Timeline

6 June 2025

Primary endpoint
27 November 2025

27 November 2025

Quick facts

Lead sponsor	Swedish Orphan Biovitrum
Status	Completed
Study type	OBSERVATIONAL
Enrollment	32
Start date	6 June 2025
Primary completion	27 November 2025
Estimated completion	27 November 2025
Sites	2 locations across Italy

Conditions studied

Macrophage Activation Syndrome (MAS) — all drugs for Macrophage Activation Syndrome (MAS) →
Still Disease, Juvenile Onset — all drugs for Still Disease, Juvenile Onset →
Still's Disease, Adult-Onset — all drugs for Still's Disease, Adult-Onset →

Sponsor

Swedish Orphan Biovitrum — full company profile →

Who can join

Adults 6 Months to 80, any sex, with Macrophage Activation Syndrome (MAS) or Still Disease, Juvenile Onset. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assessment of macrophage activation syndrome in Still's disease: retrospective chart analysis of patient history, symptom resolution and treatment characteristics in Italy

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Swedish Orphan Biovitrum trials

Trials by the same sponsor.

NCT06666335 — A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF · Phase 4 · not yet recruiting
NCT06782373 — A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) · Phase 2 · recruiting
NCT06579144 — Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A · Phase 1 · recruiting
NCT06405152 — Assessment of Macrophage Activation syndromE in STill's Disease · completed
NCT05856266 — An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroct · Phase 4 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06992505 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Swedish Orphan Biovitrum
Last refreshed: 2 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06992505.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing